

Marwan Fakih

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5532354/marwan-fakih-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

201 papers	8,510 citations	45 h-index	88 g-index
217 ext. papers	11,690 ext. citations	5.4 avg, IF	6.28 L-index

#	Paper	IF	Citations
201	Exploratory biomarker analyses of the single-arm, phase 2 study of regorafenib plus nivolumab in patients (pts) with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 89-89	2.2	
200	Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	2
199	Safety and efficacy of pressurized intraperitoneal aerosolized chemotherapy in appendiceal and colorectal cancer patients with peritoneal carcinomatosis: A first-in-US phase I study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 125-125	2.2	
198	Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS669-TPS669	2.2	
197	A single-center comparative surveillance strategies of ctDNA (Signatera), imaging, and CEA in the surveillance of resected colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 200-200	2.2	1
196	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. 2022 , 10,		2
195	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with Fusion-Positive Solid Tumors.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	10
194	A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses.. <i>Advances in Radiation Oncology</i> , 2022 , 7, 100807	3.3	0
193	Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e221093	10.4	3
192	Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy.. <i>Science Advances</i> , 2022 , 8, eabl9171	14.3	1
191	Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 670-674	7.3	0
190	Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. <i>Science Advances</i> , 2021 , 7, eabi7511	14.3	3
189	MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 72-78	3.8	2
188	Building External Control Arms From Patient-Level Electronic Health Record Data to Replicate the Randomized IMblaze370 Control Arm in Metastatic Colorectal Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 450-458	5.2	2
187	Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 1347-1357	5.4	2
186	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2021 , 22, 779-789	21.7	53
185	Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. <i>Future Oncology</i> , 2021 , 17, 1977-1985	3.6	3

184	Wild-type APC Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer. <i>Oncologist</i> , 2021 , 26, 208-214	5.7	4
183	Chemotherapy-induced early transient increase and surge of CA 19-9 level in patients with pancreatic Adenocarcinoma. <i>Cancer Treatment and Research Communications</i> , 2021 , 28, 100397	2	0
182	Rationale and Design of a Telehealth Self-Management, Shared Care Intervention for Post-treatment Survivors of Lung and Colorectal Cancer. <i>Journal of Cancer Education</i> , 2021 , 36, 414-420	1.8	2
181	RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021 , 26, 469-475	5.7	1
180	Targeting KRAS in Colorectal Cancer. <i>Current Oncology Reports</i> , 2021 , 23, 28	6.3	8
179	Recall of Genomic Testing Results Among Patients with Cancer. <i>Oncologist</i> , 2021 , 26, e2302-e2305	5.7	0
178	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 2021 , 9,		2
177	Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. <i>JAMA Network Open</i> , 2021 , 4, e2118416	10.4	7
176	Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. <i>Annals of Oncology</i> , 2021 , 32, 959-967	10.3	17
175	Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, e214158	13.4	35
174	Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis. <i>JCI Insight</i> , 2021 , 6,	9.9	3
173	Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 72-72	2.2	2
172	Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series.. <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	0
171	Locally advanced anal small cell carcinoma with durable complete response to chemoradiation followed by consolidation chemotherapy: case report and literature review.. <i>Journal of Gastrointestinal Oncology</i> , 2021 , 12, 3148-3154	2.8	0
170	Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer. <i>Oncologist</i> , 2020 , 25, e1188-e1194	5.7	24
169	Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
168	The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report. <i>Frontiers in Oncology</i> , 2020 , 10, 581	5.3	1
167	Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. <i>Cancers</i> , 2020 , 12,	6.6	9

166	Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020 , 25, 235-243	5.7	20
165	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020 , 26, 2124-2130	12.9	69
164	Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: A randomized controlled trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 12010-12010	2.2	46
163	Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3605-3605	2.2	22
162	A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4000-4000	2.2	37
161	CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4018-4018	2.2	11
160	Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4020-4020	2.2	10
159	Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS3661-TPS3661	2.2	5
158	Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1-1	2.2	10
157	A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. <i>Oncotarget</i> , 2020 , 11, 1334-1343	3.3	6
156	Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 798-804	7.3	13
155	Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3504-3504	2.2	0
154	The Association of Tumor Laterality and Survival After Cytoreduction for Colorectal Carcinomatosis. <i>Journal of Surgical Research</i> , 2020 , 248, 20-27	2.5	8
153	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. <i>Lancet Oncology, The</i> , 2020 , 21, 271-282	21.7	454
152	A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases. <i>Oncologist</i> , 2020 , 25, 382-e776	5.7	7
151	Management Considerations for the Surgical Treatment of Colorectal Cancer During the Global Covid-19 Pandemic. <i>Annals of Surgery</i> , 2020 , 272, e98-e105	7.8	18
150	A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer. <i>International Journal of Cancer</i> , 2020 , 147, 3250-3261	7.5	4
149	SUMOylation of E2F1 Regulates Expression of EZH2. <i>Cancer Research</i> , 2020 , 80, 4212-4223	10.1	7

148	KRAS Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020 , 383, 1207-1217	59.2	469
147	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <i>Lancet Oncology, The</i> , 2020 , 21, 1353-1365	21.7	500
146	Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	4
145	Co-stimulatory and co-inhibitory immune markers in solid tumors with alterations. <i>Future Science OA</i> , 2020 , 7, FSO662	2.7	0
144	Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 116-119	7.3	0
143	Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 307-309	3.8	3
142	Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019 , 30, 1096-1103	10.3	247
141	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2019 , 20, 849-861	21.7	201
140	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology, The</i> , 2019 , 20, 518-530	21.7	199
139	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1460-1469	2.2	114
138	Systemic treatment for metastatic colorectal cancer in the era of precision medicine. <i>Journal of Surgical Oncology</i> , 2019 , 119, 564-582	2.8	35
137	A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction. <i>Oncologist</i> , 2019 , 24, 1137-1145	5.7	1
136	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019 , 25, 7035-7045	12.9	72
135	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. <i>Nature</i> , 2019 , 575, 217-223	50.4	703
134	Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4464-4476	15.9	35
133	Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3003-3003	2.2	108
132	Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 688-688	2.2	12
131	Impact of Surgical Resection on Survival Outcomes After Chemoradiotherapy in Anal Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1203-1210	7.3	6

130	PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1026-1030	7.3	6
129	A case of class 3 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors. <i>Journal of Gastrointestinal Oncology</i> , 2019 , 10, 1140-1143	2.8	4
128	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. <i>Oncologist</i> , 2019 , 24, 1340-1347	5.7	43
127	Validation of Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-13	3.6	14
126	Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme. <i>Cell Chemical Biology</i> , 2019 , 26, 278-288.e6	8.2	29
125	A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. <i>Cancer Discovery</i> , 2019 , 9, 384-395	24.4	67
124	Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. <i>Journal of Gastrointestinal Oncology</i> , 2019 , 10, 161-165	2.8	9
123	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. <i>Cancer</i> , 2018 , 124, 1358-1373	6.4	87
122	Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer. <i>Oncologist</i> , 2018 , 23, 474-477	5.7	10
121	Rationale, development, and design of the Altering Intake, Managing Symptoms (AIMS) dietary intervention for bowel dysfunction in rectal cancer survivors. <i>Contemporary Clinical Trials</i> , 2018 , 68, 61-66	2.3	7
120	BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 627-627	2.2	28
119	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. <i>Journal of Gastrointestinal Oncology</i> , 2018 , 9, 610-617	2.8	131
118	Immune profiling of microsatellite instability-high and polymerase β -mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. <i>Journal of Gastrointestinal Oncology</i> , 2018 , 9, 404-415	2.8	34
117	Value-based genomics. <i>Oncotarget</i> , 2018 , 9, 15792-15815	3.3	30
116	Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 142-147	7.3	132
115	Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 962-969	2.8	16
114	Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 1079-1099	2.8	22
113	Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 314-323	2.8	3

112	Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. <i>European Journal of Oncology Nursing</i> , 2017 , 29, 125-134	2.8	25
111	Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. <i>Cancer</i> , 2017 , 123, 345-356	6.4	60
110	Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. <i>Oncotarget</i> , 2017 , 8, 42198-42213	3.3	30
109	A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres versus SIR-Spheres alone in chemotherapy-resistant colorectal cancer liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 608-613	2.8	2
108	Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 676-676	2.2	29
107	A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. <i>Oncotarget</i> , 2017 , 8, 79750-79760	3.3	7
106	MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. <i>Anticancer Research</i> , 2017 , 37, 2831-2838	2.3	10
105	Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal. <i>Nature Communications</i> , 2016 , 7, 12326	17.4	47
104	Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy. <i>Acta Oncologica</i> , 2016 , 55, 1392-1399	3.2	31
103	Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. <i>Pancreas</i> , 2016 , 45, 286-92	2.6	9
102	The state of regional therapy in the management of metastatic colorectal cancer to the liver. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 229-45	3.5	5
101	HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3517-3517	2.2	48
100	Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases. <i>World Journal of Gastrointestinal Oncology</i> , 2016 , 8, 128-35	3.4	10
99	Impressive response to dual and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. <i>Journal of Gastrointestinal Oncology</i> , 2016 , 7, E98-E102	2.8	37
98	RAS and BRAF in metastatic colorectal cancer management. <i>Journal of Gastrointestinal Oncology</i> , 2016 , 7, 687-704	2.8	39
97	Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. <i>Journal of Oncology Practice</i> , 2016 , 12, e1025-e1034	3.1	54
96	Pilot study of an interdisciplinary supportive care planning intervention in pancreatic cancer. <i>Supportive Care in Cancer</i> , 2016 , 24, 3417-24	3.9	9
95	Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. <i>Clinical Therapeutics</i> , 2016 , 38, 1376-1391	3.5	9

94	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 1306-1314	5.7	27
93	Metastatic colorectal cancer: current state and future directions. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1809-24	2.2	320
92	Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. <i>Journal of Medical Economics</i> , 2015 , 18, 619-28 ^{2.4}		5
91	Vitamin D and colorectal cancer: is it time for D3 supplementation in patients with metastatic disease?. <i>Colorectal Cancer</i> , 2015 , 4, 59-62	0.8	1
90	Biologic therapies in colorectal cancer: indications and contraindications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , e197-206 ^{7.1}		5
89	Accuracy of computed tomography in nodal staging of colon cancer patients. <i>World Journal of Gastrointestinal Surgery</i> , 2015 , 7, 116-22	2.4	12
88	p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. <i>Clinical Cancer Research</i> , 2014 , 20, 4459-70	12.9	17
87	SIR-Spheres [®] radioembolization in the management of metastatic colorectal cancer: a medical oncology perspective. <i>Colorectal Cancer</i> , 2014 , 3, 331-343	0.8	
86	A case of fibrolamellar cancer with a palliative response and minor radiographic regression with erlotinib and bevacizumab combination therapy. <i>American Journal of Therapeutics</i> , 2014 , 21, e207-10	1	8
85	The emerging role of neoadjuvant chemotherapy for rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2014 , 5, 362-73	2.8	18
84	Serum vitamin D metabolites in colorectal cancer patients receiving cholecalciferol supplementation: correlation with polymorphisms in the vitamin D genes. <i>Hormones and Cancer</i> , 2013 , 4, 242-50	5	24
83	Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine. <i>Future Oncology</i> , 2013 , 9, 551-60	3.6	8
82	TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. <i>Cancer</i> , 2013 , 119, 4290-8	6.4	47
81	The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 427-38	3.5	12
80	Targeting angiogenesis beyond first-line bevacizumab progression: ziv-aflibercept or more bevacizumab?. <i>Colorectal Cancer</i> , 2013 , 2, 9-12	0.8	0
79	A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. <i>Cancer Medicine</i> , 2013 , 2, 334-42	4.8	44
78	Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 531-46	7.3	334
77	Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 141-52; quiz 152	7.3	118

76	Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 519-28	7.3	77
75	TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells. <i>PLoS ONE</i> , 2013 , 8, e70604	3.7	21
74	Targeted therapies in colorectal cancer: the dos, don'ts, and future directions. <i>Journal of Gastrointestinal Oncology</i> , 2013 , 4, 239-44	2.8	
73	Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 2013 , 5, 178-86	2.4	8
72	A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 743-51	3.5	31
71	Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 53-9	3.8	10
70	Intensive radiographic and biomarker surveillance in stage II and III colorectal cancer. <i>Oncology</i> , 2012 , 82, 41-7	3.6	14
69	Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 449-54	7.3	56
68	Interview: Recent advances in first-line treatment of metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2012 , 1, 111-114	0.8	
67	Intensive screening for resected stage II and III colorectal cancer. <i>Colorectal Cancer</i> , 2012 , 1, 71-81	0.8	
66	Rectal cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 1528-64	7.3	127
65	Methyl selenocysteine: single-dose pharmacokinetics in men. <i>Cancer Prevention Research</i> , 2011 , 4, 1938-44	3.4	20
64	Serological immune responses to influenza vaccine in patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 111-5	3.5	15
63	Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. <i>Prostate</i> , 2011 , 71, 368-72	4.2	46
62	Making sense of anti-EGFR plus oxaliplatin-based therapy in the first-line treatment of metastatic colorectal cancer. <i>Future Oncology</i> , 2011 , 7, 223-6	3.6	
61	Vitamin D and Colorectal Cancer 2011 , 295-313		
60	First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases. <i>Anticancer Research</i> , 2011 , 31, 975-8	2.3	33
59	Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. <i>Anticancer Research</i> , 2011 , 31, 4637-40	2.3	22

58	Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4240-6	2.2	115
57	A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. <i>Clinical Cancer Research</i> , 2010 , 16, 3786-94	12.9	36
56	KRAS mutation screening in colorectal cancer: From paper to practice. <i>Clinical Colorectal Cancer</i> , 2010 , 9, 22-30	3.8	16
55	NCCN clinical practice guidelines in oncology. Anal carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 106-20	7.3	53
54	Quantitative methodology using CT for predicting survival in patients with metastatic colorectal carcinoma: a pilot study. <i>Clinical Imaging</i> , 2010 , 34, 196-202	2.7	1
53	Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 76, 1193-8	4	10
52	Renal atrophy secondary to chemoradiotherapy of abdominal malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 539-46	4	15
51	Predictive or non-predictive, prognostic or non-prognostic: Dilemmas generated through small retrospective studies. <i>Journal of Gastrointestinal Oncology</i> , 2010 , 1, 72-3	2.8	1
50	Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. <i>Current Oncology</i> , 2010 , 17 Suppl 1, S3-17	2.8	44
49	KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2010 , 1, 90-6	2.8	6
48	Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation. <i>World Journal of Gastrointestinal Oncology</i> , 2010 , 2, 213-7	3.4	7
47	A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 3189-95	12.9	54
46	Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1800-5	2.2	167
45	Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2009 , 24, 219-24	3	62
44	A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 65, 33-40	3.5	40
43	Vitamin D deficiency and insufficiency among patients with prostate cancer. <i>BJU International</i> , 2009 , 104, 909-14	5.6	36
42	A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 71, 242-8	7	14
41	Does celecoxib have a role in the treatment of patients with colorectal cancer?. <i>Clinical Colorectal Cancer</i> , 2009 , 8, 11-4	3.8	9

40	A case of 5-fluorouracil-induced acute psychosis. <i>Clinical Colorectal Cancer</i> , 2009 , 8, 166-8	3.8	2
39	NCCN Clinical Practice Guidelines in Oncology: colon cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 778-831	7.3	325
38	Qualitative radiology assessment of tumor response: does it measure up?. <i>Clinical Imaging</i> , 2008 , 32, 136-40	2.7	2
37	Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 1471-80	3.5	11
36	A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 499-508	3.5	29
35	Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N1, N11 diethylnorspermine. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 517-27	3.5	26
34	The role of targeted therapy in the treatment of advanced colorectal cancer. <i>Current Treatment Options in Oncology</i> , 2008 , 9, 357-74	5.4	5
33	Significance of signet-ring cells in patients with colorectal cancer. <i>Diseases of the Colon and Rectum</i> , 2008 , 51, 50-5	3.1	77
32	Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. <i>Oncology</i> , 2008 , 22, 74-6	1.8	30
31	Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy. <i>Clinical Colorectal Cancer</i> , 2007 , 6, 362-6	3.8	13
30	Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. <i>Clinical Colorectal Cancer</i> , 2007 , 6, 447-9	3.8	8
29	Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities. <i>Clinical Colorectal Cancer</i> , 2007 , 6, 583-7	3.8	6
28	Safety and efficacy of first-line chemotherapy in unresected metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2007 , 6, 710-5	3.8	7
27	Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. <i>Biochemical Pharmacology</i> , 2007 , 73, 1280-7	6	22
26	Selenium metabolites in urine of cancer patients receiving L-selenomethionine at high doses. <i>Toxicology and Applied Pharmacology</i> , 2007 , 220, 211-5	4.6	28
25	A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. <i>Annals of Surgical Oncology</i> , 2007 , 14, 3202-9	3.1	64
24	A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 1216-23	12.9	67
23	Anti-EGFR monoclonal antibody-induced hypomagnesaemia. <i>Lancet Oncology</i> , 2007 , 8, 366-7	21.7	19

22	Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 57, 465-74	3.5	7
21	Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. <i>International Journal of Cancer</i> , 2006 , 118, 1777-81	7.5	66
20	Bevacizumab-induced nasal septum perforation. <i>Oncologist</i> , 2006 , 11, 85-6	5.7	38
19	Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of rectal adenocarcinoma: can we get the right dose first?. <i>Annals of Oncology</i> , 2006 , 17, 1029-30; author reply 1030-1	10.3	
18	Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. <i>Oncology</i> , 2006 , 70, 49-53	3.6	25
17	Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 687-703	4	9
16	Cetuximab-induced hypomagnesemia in patients with colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2006 , 6, 152-6	3.8	85
15	Vitamin D compounds: clinical development as cancer therapy and prevention agents. <i>Anticancer Research</i> , 2006 , 26, 2551-6	2.3	52
14	Prevention of colorectal cancer: an emerging role for high-dose vitamin D supplementation?. <i>Oncology</i> , 2006 , 20, 1707-10	1.8	1
13	Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. <i>Clinical Colorectal Cancer</i> , 2005 , 5, 132-5	3.8	40
12	Postoperative computed tomography scan surveillance for patients with stage II and III colorectal cancer: worthy of further study?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005 , 28, 30-5	2.7	9
11	Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 55, 354-360	3.5	16
10	Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2005 , 11, 5942-9	12.9	5
9	Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2004 , 10, 5058-64	12.9	16
8	First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?. <i>Annals of Oncology</i> , 2004 , 15, 359	10.3	
7	A report of high-dose selenium supplementation: response and toxicities. <i>Journal of Trace Elements in Medicine and Biology</i> , 2004 , 18, 69-74	4.1	144
6	Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 487-96	3.5	20
5	Anti-tumor activity of calcitriol: pre-clinical and clinical studies. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2004 , 89-90, 519-26	5.1	131

4	Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. <i>Urology</i> , 2002 , 60, 553-61	1.6	55
3	Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma: a series of six cases. <i>Annals of Oncology</i> , 2001 , 12, 1173-7	10.3	54
2	Unusual tumors involving the head and neck region: case 1. Angiosarcoma of the scalp. <i>Journal of Clinical Oncology</i> , 2001 , 19, 4173-4	2.2	9
1	Inhibition of prostate cancer growth by estramustine and colchicine. <i>Prostate</i> , 1995 , 26, 310-5	4.2	24